Clinical trials
Phase 3 trials in Georgia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
409 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 12 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 12 |
| 2014 | 21 |
| 2015 | 20 |
| 2016 | 20 |
| 2017 | 21 |
| 2018 | 27 |
| 2019 | 27 |
| 2020 | 29 |
| 2021 | 47 |
| 2022 | 27 |
| 2023 | 27 |
| 2024 | 43 |
| 2025 | 27 |
| 2026 | 20 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 230 |
| Active, not recruiting | 59 |
| Recruiting | 55 |
| Terminated | 51 |
| Unknown status | 7 |
| Enrolling by invitation | 6 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| argenx | 19 |
| Sanofi | 13 |
| Boehringer Ingelheim | 12 |
| UCB Biopharma SRL | 9 |
| Alvotech Swiss AG | 8 |
| Celgene | 8 |
| Teva Branded Pharmaceutical Products R&D, Inc. | 8 |
| Amgen | 7 |
| Hoffmann-La Roche | 7 |
| Regeneron Pharmaceuticals | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 20 |
| Myasthenia Gravis | 16 |
| Breast Neoplasms | 15 |
| Colitis, Ulcerative | 15 |
| Multiple Sclerosis | 13 |
| Crohn Disease | 11 |
| Autoimmune Diseases | 9 |
| Multiple Sclerosis, Relapsing-Remitting | 9 |
| Neoplasm Metastasis | 9 |
| Epilepsy | 8 |
Trials
Showing 26 to 50 of 409. Each trial links to its page on Pharma Observatory.
309 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.